menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Pfizer`s blockbuster ADC Adcetris nabs FDA nod in LBCL

    FDA

    Ottimo raises $140M to ready PD1/VEGFR2 antibody for clinic

    FIERCE BIOTECH

    Pfizer tacks on $1B to 2024 revenue outlook amid cost-cutting drive

    PRESS RELEASE

    Pfizer to press pause on large M&A deals, CEO says

    FIERCE PHARMA

    Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

    ENDPTS

    Pfizer telegraphs another round of Seagen layoffs

    FIERCE PHARMA

    Pfizer lifts profit view on cost cuts, demand for COVID products

    REUTERS

    Seagen’s former commercial chief joins the board at healthcare agency

    ENDPTS

    Seagen patent invalidated in long-running Daiichi Sankyo spat

    FIERCE PHARMA

    Patent Office Invalidates Seagen Patent in Dispute between Daiichi and Seagen

    BUSINESSWIRE

    Pfizer`s $43B buyout of ADC specialist Seagen is a done deal

    FIERCE PHARMA

    Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

    REUTERS

    ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

    BUSINESSWIRE

    TUKYSA® Improves Progression-Free Survival in Patients with Breast Cancer

    BUSINESSWIRE

    Overall survival data blur Seagen`s Tukysa-ADC path

    FIERCE PHARMA

    Seagen Highlights First Solid Tumor Data for an ADCETRIS

    BUSINESSWIRE

    Data for ADCETRIS with Combination in Hodgkin Lymphoma to be Featured

    BUSINESSWIRE

    Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth

    BUSINESSWIRE

    EV-302 Trial Extends OS in Patients Treated with PADCEV & KEYTRUDA in Bladder Cancer

    BUSINESSWIRE

    Pfizer’s $43 billion purchase of Seagen gets green light from EU antitrust

    CNBCTV18

    District Court issues final judgment in patent dispute between Daiichi & Seagen

    PHRAMABIZ

    ESMO: Padcev-Keytruda combo nearly doubles survival in key trial

    FIERCE PHARMA

    Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK®

    BUSINESSWIRE

    Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023

    BUSINESSWIRE

    Padcev, Keytruda combo posts `practice-changing` win

    FIERCE PHARMA

    Nurix Announces Collaboration with Seagen Combining Leading Technologies

    GLOBENEWSWIRE

    Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

    GLOBENEWSWIRE

    Seagen`s breast cancer drug Tukysa boosts Roche`s ADC

    FIERCE PHARMA

    Seagen says Tukysa combo hits main goal in Phase III breast cancer study

    BUSINESSWIRE

    Seagen puts $1.6B Merck-partnered ADC on the back burner

    FIERCE BIOTECH

    Seagen Second Quarter 2023 Financial Results Demonstrate Commercial Performance

    BUSINESSWIRE

    Pfizer shuffles R&D leadership to prepare for Seagen merger

    FIERCE BIOTECH

    US FTC seeks additional info on Pfizer`s proposed takeover of Seagen

    REUTERS

    FTC says it wants more information about $43B Pfizer-Seagen deal

    ENDPTS

    Seagen to Report Second Quarter 2023 Financial Results on August 2, 2023

    BUSINESSWIRE

    Former Seagen CEO brings company HQ to Seattle after merger

    BIZJOURNAL

    Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit

    PRESS RELAESE

    Ph3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows

    BUSINESSWIRE

    FDA advisers back XBB-targeted COVID shots for 2023-24 campaign

    REUTERS

    Pfizer refiles Seagen acquisition paperwork

    ENDPTS

    Seattle`s Biologic Adcetris (Brentuximab Vedotin) Receives Approval in the U.S.

    FDA

    Pfizer withdraws $43B Seagen buyout notification to refile

    FIERCE PHARMA

    6-Year Overall Survival Results Added to Prescribing Information for ADCETRIS

    BUSINESSWIRE

    Seagen touts PhII data for Adcetris combo; A-Alpha partners with Gilead on HIV

    ENDPTS

    Seagen Announces ADCETRIS Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate

    BUSINESSWIRE

    Second round of inflation-related rebates hits 43 drugs from Amgen and others

    ENDPTS

    Seagen CEO Epstein on his next stop, the Pfizer deal and ADCs

    FIERCE PHARMA

    ASCO: Seagen`s top-selling drug under threat from Opdivo

    FIERCE PHARMA

    Seagen Stockholders Approve Acquisition by Pfizer

    BIOSPACE

    Pfizer to raise $31 billion for Seagen takeover in largest debt offering

    REUTERS

    FTC move on Amgen-Horizon doesn`t doom Pfizer-Seagen: analysts

    FIERCE PHARMA

    Pfizer, Seagen kick off FTC review of $43B merger

    FIERCE PHARMA

    After Pfizer-Seagen deal, analysts expect more M&A activity

    FIERCE PHARMA

    Biopharma Bets Big on Antibody-Drug Conjugates

    BIOSPACE

    Seagen Reports First Quarter 2023 Financial Results

    BUSINESSWIRE

    Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 ASCO

    BUSINESSWIRE

    In $43B buy, Seagen courted Pfizer and played the waiting game

    FIERCE PHARMA

    Seagen to Report First Quarter 2023 Financial Results on April 27, 2023

    BUSINESSWIRE

    Merck and Seagen`s Padcev-Keytruda combo wins bladder cancer nod

    PRESS RELEASE

    Former Seagen CEO takes new role less than a year after arrest

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.